首页> 外文期刊>International Journal of Chronic Obstructive Pulmonary Disease >Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years
【24h】

Use of medicines and health services for chronic obstructive pulmonary disease among a cohort of Australians over 50 years

机译:超过50年的澳大利亚人群中使用药物和卫生服务治疗慢性阻塞性肺疾病

获取原文
           

摘要

Background: It is not known if the medicines and services for COPD are used in Australia according to the COPD-X guideline. This study examined the use of medicines and health services for COPD among an Australian cohort to determine if they were consistent with recommendations. Methods: The administrative claims data from the Australian Government Department of Veterans’ Affairs were used and included persons aged ≥50 years who were using medicines for COPD in April 2016. Use of medicines was identified using the Anatomical, Therapeutic and Chemical Classification and Pharmaceutical Benefits Scheme. Use of services was identified using the Medicare Benefits Schedule and Australian Government Department of Veterans’ Affairs Fee Schedule. Results: Of the 143,261 persons aged ≥50 years, 12,623 (8.8%) were on medicines for COPD. Of the total COPD population, 42% were managed on monotherapy, 36% on dual therapy, 21% on triple therapy, and 1.5% on more than three COPD medicines. Monotherapy comprised tiotropium (80%) predominantly. Services to practitioners who may provide pulmonary rehabilitation service showed less than 10% of the cohort had a claim for a visit to an exercise physiologist and less than a third had a claim for a physiotherapist visit in the prior 12 months. Services to assist with care coordination in the form of general practitioner management plans were only claimed by half of the cohort, while services supporting appropriate medicine use were claimed by less than one in six cases, despite high levels of inhaler use and multiple inhaler use. Conclusion: More than three-quarters of COPD persons aged 50 years and above were managed on either monotherapy or dual therapy, consistent with the guideline recommendations. Almost one-quarter was on three or more therapies, which will create challenges for multiple device management. Many services that may benefit persons with COPD appear to be underutilized.
机译:背景:目前尚不清楚是否根据COPD-X指南在澳大利亚使用了COPD的药物和服务。这项研究检查了澳大利亚人群中COPD的药物和保健服务的使用情况,以确定它们是否与建议相符。方法:使用澳大利亚政府退伍军人事务部的行政要求数据,包括2016年4月使用药物治疗COPD的年龄≥50岁的人。药物的使用根据解剖学,治疗学和化学分类以及药物益处进行识别方案。服务的使用是根据《医疗保险给付表》和《澳大利亚政府退伍军人事务费表》确定的。结果:在143,261名年龄≥50岁的人中,有12,623名(8.8%)正在服用COPD药物。在全部COPD人群中,有42%采用单药治疗,36%采用双重疗法,21%采用三联疗法,以及1.5%以上使用三种以上的COPD药物。单一疗法主要包括噻托溴铵(80%)。对可能提供肺康复服务的从业人员的服务显示,在过去的12个月中,只有不到10%的队列有运动生理学家的拜访,少于三分之一的队列中有物理治疗师的拜访。尽管全民吸入器使用率高且使用了多次吸入器,但只有一半的队列研究者要求以全科医生管理计划的形式提供协助护理协调的服务,而不到六分之一的人主张支持适当药物使用的服务。结论:与指南建议一致,超过四分之三的50岁及以上的COPD患者接受了单一疗法或双重疗法的治疗。几乎四分之一的患者接受了三种或更多种疗法,这将给多设备管理带来挑战。许多可能使COPD患者受益的服务未得到充分利用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号